GoodRx Holdings, Inc.GDRXNASDAQ
Loading
GoodRx operates a prescription drug price comparison platform connecting 6+ million monthly active consumers with 70,000+ pharmacies across the US, monetizing through pharmacy benefit manager (PBM) referral fees and subscription services. The company captures value by aggregating fragmented pharmacy pricing and negotiating discounts, positioning between cash-pay consumers and retail pharmacies. Recent 56% stock decline reflects competitive pressure from Amazon Pharmacy, Mark Cuban Cost Plus Drugs, and declining prescription transaction volumes.
GoodRx negotiates discount rates with PBMs (OptumRx, Caremark, Express Scripts) and earns a percentage of each prescription filled using its platform, typically $3-8 per transaction. The business model relies on high-margin referral economics (94% gross margin) with minimal variable costs per transaction. Competitive advantage stems from network effects (pharmacy coverage breadth), brand recognition among cash-pay consumers, and SEO dominance for drug pricing searches. Pricing power is limited as PBMs control reimbursement rates and can reduce referral fees, evidenced by margin pressure in 2024-2025.
Monthly active consumer (MAC) growth and retention rates - declining MACs signal competitive displacement
Revenue per transaction trends - PBM rate compression directly impacts unit economics
Prescription transaction volume growth - reflects market share in cash-pay and underinsured segments
Competitive announcements from Amazon Pharmacy, Mark Cuban Cost Plus Drugs, or Walmart Health expansions
Regulatory changes to PBM rebate structures or pharmacy reimbursement models
Disintermediation by integrated pharmacy-PBM models: Amazon Pharmacy, CVS Health, and Walgreens vertical integration threatens GoodRx's intermediary position as pharmacies bypass third-party platforms
Regulatory changes to PBM rebate structures: Federal transparency initiatives or state-level PBM regulations could eliminate spread pricing that funds GoodRx referral fees
Medicare negotiation expansion: IRA drug price negotiations reducing list prices diminishes value proposition of discount cards for cash-pay consumers
Amazon Pharmacy's RxPass ($5/month unlimited generics) and Prime integration offering superior convenience and pricing for common medications
Mark Cuban Cost Plus Drugs' cost-plus-15% model providing transparent pricing that undercuts GoodRx on many generics
Direct-to-consumer telehealth platforms (Hims & Hers, Ro) bundling prescriptions with consultations, bypassing traditional pharmacy channels
Moderate debt load ($73M net debt, 0.91 D/E) manageable but limits financial flexibility for acquisitions or competitive investments during margin compression
Declining cash generation: Free cash flow of $100M (15% yield) is strong but down from historical levels, constraining buyback capacity to offset dilution
moderate - GoodRx benefits from economic stress as more consumers become uninsured or underinsured, driving cash-pay prescription demand. However, severe recessions reduce overall prescription utilization and shift consumers toward generic alternatives with lower transaction values. The 2023-2024 period showed resilience as inflation-pressured consumers sought savings, but discretionary prescription categories (weight loss, dermatology) exhibit cyclical sensitivity.
Rising rates negatively impact valuation multiples for unprofitable growth companies, though GoodRx achieved GAAP profitability in 2025. Higher rates increase discount rates applied to future cash flows, compressing the 0.9x P/S multiple from 2021 IPO levels of 15x+. Operationally, rate changes have minimal direct impact as the business carries modest debt ($73M net debt) and generates positive free cash flow. However, rates affect consumer discretionary spending on non-essential prescriptions.
Minimal direct credit exposure. GoodRx operates asset-light with strong liquidity (3.1x current ratio, $200M+ cash). The business model does not involve lending or credit underwriting. Indirect exposure exists through consumer credit conditions affecting prescription affordability and pharmacy partner financial health, but these are secondary factors.
value - Stock trades at 0.9x P/S and 5.8x EV/EBITDA with 15% FCF yield, attracting deep value investors betting on stabilization. The 56% decline has created contrarian opportunity for investors believing competitive threats are overestimated. Not a growth stock given 5.6% revenue growth and structural headwinds. Dividend investors excluded (no dividend). Momentum investors exited during 2024-2025 drawdown.
high - Beta likely 1.5+ given small-cap status ($800M market cap), competitive disruption narrative, and illiquidity. Stock exhibits event-driven volatility around competitive announcements (Amazon Pharmacy updates, Mark Cuban expansions) and quarterly earnings. Recent 40% six-month decline demonstrates downside volatility risk.